Neurocrine Biosciences (NASDAQ:NBIX) Given New $192.00 Price Target at HC Wainwright

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective reduced by HC Wainwright from $198.00 to $192.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently weighed in on the company. Stifel Nicolaus upped their target price on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Truist Financial lowered their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating for the company in a report on Thursday, January 8th. UBS Group reduced their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Morgan Stanley reiterated an “equal weight” rating and issued a $175.00 price target (up previously from $173.00) on shares of Neurocrine Biosciences in a research note on Thursday, January 8th. Finally, Citigroup increased their price objective on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Fifteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $177.56.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $123.10 on Thursday. The business has a 50 day moving average price of $140.77 and a 200-day moving average price of $140.46. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $160.18. The firm has a market cap of $12.27 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31.

Insiders Place Their Bets

In other news, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the transaction, the insider directly owned 43,405 shares in the company, valued at $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Leslie V. Norwalk sold 5,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $152.23, for a total transaction of $761,150.00. Following the completion of the transaction, the director directly owned 7,429 shares in the company, valued at $1,130,916.67. This trade represents a 40.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,966 shares of company stock valued at $8,625,166 over the last three months. Insiders own 4.80% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the business. USA Financial Formulas purchased a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $25,000. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC lifted its position in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after buying an additional 100 shares during the last quarter. Eastern Bank bought a new stake in Neurocrine Biosciences in the third quarter worth $27,000. Finally, DJE Kapital AG purchased a new position in Neurocrine Biosciences during the fourth quarter worth $28,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.